Reinstating immunogenicity using bispecific anti-checkpoint/agent inhibitors

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Immune checkpoint inhibitor (ICI) resistance is a significant challenge in treating advanced cancers.
• Novel therapeutic strategies are needed to broaden the effectiveness of cancer immunotherapy.

Purpose of the Study:

• To explore bispecific antibodies as an emerging therapeutic paradigm in cancer immunotherapy.
• To evaluate the potential of bispecific antibodies in overcoming ICI resistance and improving treatment outcomes.

Main Methods:

• Investigating synchronous inhibition of immune checkpoints like PD-1, PD-L1, and CTLA-4 using bispecific antibodies.
• Analyzing the formation of immunological synapses within the tumor immune microenvironment (TIME).
• Comparing the efficacy and safety of bispecific antibodies with conventional single-agent monoclonal antibodies and combination therapies.

Main Results:

• Bispecific antibodies demonstrate higher potency in reinvigorating anti-tumor immune responses compared to combined single-agent monoclonal antibodies.
• These agents effectively retard tumor growth and improve patient survival.
• Formation of immunological synapses by bispecific agents directly mediates tumor cell cytotoxicity and durable immune responses.
• Bispecific antibodies are associated with lower adverse events than individual checkpoint inhibitors.

Conclusions:

• Bispecific antibodies represent a promising approach to replace conventional combination checkpoint inhibitor therapy, especially for tumors with cold or immunosuppressive immunity.
• Further research is ongoing to fully elucidate the importance of bispecific antibodies in advancing cancer immunotherapy.